Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 3.49 is 63% above its 5-year average of 2.14, near the high end of its 5-year range (1.43–3.49).
75.40% above its 12-month average of 1.99.
Reported quarterly EPS; no daily interpolation.
Reported annual fiscal-period values; no daily interpolation.
Reported annual fiscal-period values; no daily interpolation.
EARNINGS PER SHARE (EPS)
3.49
EARNINGS PER SHARE (EPS) AVG TTM
1.99
EARNINGS PER SHARE (EPS) AVG 3Y
2.05
EARNINGS PER SHARE (EPS) AVG 5Y
2.14
EARNINGS PER SHARE (EPS) AVG 10Y
1.85
EARNINGS PER SHARE (EPS) AVG 15Y
1.75
EARNINGS PER SHARE (EPS) AVG 20Y
1.58
CURRENT VS TTM AVG
+75.40%
CURRENT VS 3Y AVG
+69.93%
CURRENT VS 5Y AVG
+63.30%
CURRENT VS 10Y AVG
+88.27%
CURRENT VS 15Y AVG
+99.96%
CURRENT VS 20Y AVG
+121.39%
Roche Holding AG
Market Cap
$359.46B
Earnings Per Share (EPS)
3.49
TTM Avg
1.99
3Y Avg
2.05
5Y Avg
2.14
Market Cap
$358.76B
Earnings Per Share (EPS)
15.55
TTM Avg
14.44
3Y Avg
18.63
5Y Avg
18.19
Market Cap
$369.34B
Earnings Per Share (EPS)
1.25
TTM Avg
7.03
3Y Avg
4.98
5Y Avg
4.65
Market Cap
$455.87B
Earnings Per Share (EPS)
3.55
TTM Avg
2.38
3Y Avg
3.54
5Y Avg
3.89
Market Cap
$255.15B
Earnings Per Share (EPS)
6.66
TTM Avg
5.57
3Y Avg
4.27
5Y Avg
3.27
Market Cap
$235.85B
Earnings Per Share (EPS)
16.09
TTM Avg
10.97
3Y Avg
11.67
5Y Avg
11.57
Market Cap
$234.38B
Earnings Per Share (EPS)
18.59
TTM Avg
17.17
3Y Avg
16.90
5Y Avg
17.22
Market Cap
$205.42B
Earnings Per Share (EPS)
4.06
TTM Avg
3.38
3Y Avg
2.82
5Y Avg
2.39
Market Cap
$193.04B
Earnings Per Share (EPS)
3.11
TTM Avg
5.71
3Y Avg
4.66
5Y Avg
4.19
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | 3.49 | 1.99 | 2.05 | 2.14 |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 15.55 | 14.44 | 18.63 | 18.19 |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 1.25 | 7.03 | 4.98 | 4.65 |
| AbbVie Inc. (ABBV)vs › | $455.87B | 3.55 | 2.38 | 3.54 | 3.89 |
| AstraZeneca PLC (AZN)vs › | $255.15B | 6.66 | 5.57 | 4.27 | 3.27 |
| Amgen Inc. (AMGN)vs › | $235.85B | 16.09 | 10.97 | 11.67 | 11.57 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 18.59 | 17.17 | 16.90 | 17.22 |
| Novo Nordisk A/S (NVO)vs › | $205.42B | 4.06 | 3.38 | 2.82 | 2.39 |
| Abbott Laboratories (ABT)vs › | $193.04B | 3.11 | 5.71 | 4.66 | 4.19 |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | -2.67 | 3.61 | 3.85 | 3.41 |
Trailing EPS (TTM)
$3.49
Forward EPS (Est.)
$2.47
P/E Ratio
16.1
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 2.55 |
| 2024-12-31 | 1.43 |
| 2023-12-31 | 2.14 |
| 2022-12-31 | 2.10 |
| 2021-12-31 | 2.25 |
| 2020-12-31 | 2.36 |
| 2019-12-31 | 2.03 |
| 2018-12-31 | 1.56 |
| 2017-12-31 | 1.29 |
| 2016-12-31 | 1.38 |
| 2015-12-31 | 1.30 |
| 2014-12-31 | 1.38 |
| 2013-12-31 | 1.81 |
| 2012-12-31 | 1.52 |
| 2011-12-31 | 1.47 |
| 2010-12-31 | 1.36 |
| 2009-12-31 | 1.09 |
| 2008-12-31 | 1.22 |
| 2007-12-31 | 1.25 |
| 2006-12-31 | 0.95 |
| 2005-12-31 | 0.67 |
| 2004-12-31 | 0.86 |
| 2003-12-31 | 0.37 |
| 2002-12-31 | -0.43 |
| 2001-12-31 | 0.33 |
| 2000-12-31 | 0.80 |
| 1999-12-31 | 0.53 |
| 1998-12-31 | 0.47 |
